BriaCell Therapeutics Corp. Warrant
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCTXZ research report →
About the company
BriaCell Therapeutics Corp. , a biotechnology company based in West Vancouver, Canada, is intensely focused on immuno-oncology, dedicated to engineering novel immunotherapies for cancer treatment. Its flagship compound, Bria-IMT, is a whole-cell cancer vaccine presently in Phase I/IIa clinical development, where it's being evaluated in conjunction with the investigational immunotherapy retifanlimab.
- CEO
- William V. Williams
- IPO
- 2025
- Employees
- 16
- HQ
- West Vancouver, BC, CA
Price Chart
- Market Cap
- $169.54K
- P/E
- -0.76
- P/S
- 0.00
- P/B
- 0.97
- EV/EBITDA
- 0.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -147.92%
- ROIC
- -136.31%
- Revenue
- $0 · 0.00%
- Net Income
- $-26,633,600 · -455.85%
- EPS
- $-62.95 · -44.12%
- Op Income
- $-27,537,455
- FCF YoY
- -16.00%
- 52W High
- $0.09
- 52W Low
- $0.08
- 50D MA
- $0.09
- 200D MA
- $0.20
- Beta
- 1.64
- Avg Volume
- 41.40K
Get TickerSpark's AI analysis on BCTXZ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BCTXZ coverage
Recent articles, reports, and earnings notes.
No research on BCTXZ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BCTXZ report →Similar companies
Peers in the same neighborhood.